Chinese Journal of Cancer Research

, Volume 16, Issue 3, pp 220–224 | Cite as

Effect of procyanidin on cell cycle in murine lewis lung carcinoma

  • Lou Jin-li 
  • Lin Hong-sheng 
  • Qiu Quan-ying 
  • Pei Ying-xia 
  • Qi Xin 
Articles
Received:
Accepted:

Abstract

Objective: To investigate the anti-tumor effect of procyanidin (WeiMaiNing, WMN) on a murine Lewis lung carcinoma cell line (3LL) and the influence on the cell cycle. Methods: The inhibitory rate of 3LL growth was detected in the model of murine Lewis lung carcinoma. The effect of the drug on 3LL cell cycle and the influence of the drug on the expression of cyclin D1 protein were investigated by flow cytometry, immunohistochemical staining. Results: The inhibitory rates of WMN in 3LL were 19.14%, 33.59% and 51.56% respectively at dosages 100 mg·kg−1·d−1, 150 mg·kg−1·−1 and 250 mg·kg−1·d−1. The inhibitory effect was in a dose-dependent manner. We found WMN significantly increased (P<0.01) the number of 3LL cells in G0–G1 phase (35.97% vs. 27.2% at 150 mg·kg−1·−1 WMN; 40.10% vs. 27.2% at 250 mg·kg−1·−1 WMN) and decreased the expression of cyclin D1, PCNA protein. Conclusion: WeiMaiNing inhibits the growth of 3LL cells in vivo by decreasing the expression of PCNA and cyclin D1, blocking the cells in G0–G1 phase and preventing the cells transition from G1 to S phase while DNA is replicated.

Key word

Procyanidin Lewis lung carcinoma Cyclin D1 PCNA 

CLC number

R73-36 
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Chen PK. Inhibition of tumor growth in vitro by the extract of fagopyrum cymosum [J]. Life Sciences 2003; 72:1851–8.CrossRefGoogle Scholar
  2. [2]
    Semczuk A, Jakowicki JA. Alterations of pRb1-cyclin D1-cdk4/6-p16 (INK4A) pathway in endometrial carcinogenesis [J]. Cancer Lett 2004; 203:1–12.PubMedCrossRefGoogle Scholar
  3. [3]
    MotoKura T, A Arnold. Cyclins and oncogenesis [J]. Biochim Biophys Acta 1993; 1155:63–78.PubMedGoogle Scholar
  4. [4]
    Senderowicz AM. Cell cycle modulators for the treatment of lung malignancies [J]. Clin Lung Cancer 2003; 5:158–68.PubMedCrossRefGoogle Scholar
  5. [5]
    Marx J. How cells cycle toward cancer [J]. Science 1994; 263:319–21.PubMedCrossRefGoogle Scholar
  6. [6]
    Giermasz A, Makowski M, Kozlowska E, et al. Potentiating antitumor effects of a combination therapy with lovastatin and butyrate in the Lewis lung carcinoma model in mice [J]. Int J Cancer 2002; 97:746–50.PubMedCrossRefGoogle Scholar
  7. [7]
    Quelle DE, Ashmun RA, Shurtleff SA, et al. Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblast [J]. Genes Dev 1993; 7:1559–1671.PubMedCrossRefGoogle Scholar
  8. [8]
    Xiong Y, Zhang H, Beach D. D type cyclins associate with multiple protein kinases and the DNA replicates factor PCNA [J]. Cell 1992; 71:505–14.PubMedCrossRefGoogle Scholar
  9. [9]
    Caputi M, Groeger AM, Esposito V, et al. Prognostic role of cyclin D1 in lung cancer. Relationship to proliferating cell nuclear antigen [J]. Am J Respir Cell MolBiol 1999; 20:746–50.Google Scholar

Copyright information

© the Editorial Board of Chinese Journal of Cancer Research 2004

Authors and Affiliations

  • Lou Jin-li 
    • 1
  • Lin Hong-sheng 
    • 2
  • Qiu Quan-ying 
    • 1
  • Pei Ying-xia 
    • 2
  • Qi Xin 
    • 2
  1. 1.Department of Microbiology and ImmunologyBeijing University of Traditional Chinese MedicineBeijing
  2. 2.Tumor Laboratory, Guanganmen HospitalChina Academy of Traditional Chinese MedicineBeijing

Personalised recommendations